This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by LOBO, R. A. Articles by HORTON, R. Search for Related Content PubMed PubMed Citation Articles by LOBO, R. A. Articles by HORTON, R.

Evidence for the Importance of Peripheral Tissue Events in the Development of Hirsutism in Polycystic Ovary Syndrome^*

Department of Obstetrics and Gynecobgy, and Medicine, University of Southern California School of Medicine Los Angeles, California 90033

Address correspondence and requests for reprints to: Rogerio A. Lobo, M.D., Women’s Hospital, Room 1012,1240 North Mission Road, Los Angeles, California 90033.

Hirsutism can occur in the presence of normal or near normal levels of serum testosterone, unbound testosterone (uT), dehydroepiandrostene sulfate, androstenedione, and dihydrotestosterone. However, we have found that serum androstanediol glucuronide (3-diol G) is markedly increased in idiopathic hirsutism and it serves as an excellent marker of peripheral androgen metabolism and action. In the present work, we studied 12 hirsute (H) and 12 nonhirsute (NH) patients with polycystic ovary syndrome (PCO) and 13 age and weight matched controls in order to determine if differences in sex steroid levels or peripheral tissue androgen events were associated with hirsutism. Serum unbound estradiol levels and LHFSHratios were similar in both groups of women with PCO, and both were significantly higher than levels in controls (P < 0.05). Whereas serum testosterone, uT, and androstenedione were elevated in both H-PCO and NH-PCO patients compared to controls, the levels in these two groups were similar. Serum dehydroepiandrostene sulfate was higher in PCO patients comparedcompared to controls, but H-PCO patients had slightly higher levels than NH-PCO patients. Serum 5-androstenediol was also slightly higher in H-PCO compared to NH-PCO patients. Dihydrotestosterone was normal and unconjugated; 3-diol was higher than normal in both groups of patients with PCO, although H-PCO patients had higher levels than NH-PCO patients. Compared to these relatively minor changes between the PCO patient groups, serum 3-diol G was markedly elevated in H-PCO patients (approximately 10-fold), yet normal in NHPCO patients (P < 0.01). The ratios of serum 3-diol G-uT were similar in NH-PCO patients and controls, but were elevated in H-PCO patients (P < 0.01). These data indicate that: 1) women with PCO have increased circulating androgen levels regardless of the presence or absence of hirsutism; and 2) the presence of hirsutism is not only a function of circulating androgen levels, but may also be determined by events in peripheral tissues.

^* Supported in part by Grant 690-0650A from the Ford Foundation and Grant AM-13710 from NIH.

Received November 29, 1982.

This article has been cited by other articles:

				K. A. Martin, R. J. Chang, D. A. Ehrmann, L. Ibanez, R. A. Lobo, R. L. Rosenfield, J. Shapiro, V. M. Montori, and B. A. Swiglo Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1105 - 1120. [Abstract] [Full Text] [PDF]

				Y. O. Tanaka, H. Tsunoda, Y. Kitagawa, T. Ueno, H. Yoshikawa, and Y. Saida Functioning Ovarian Tumors: Direct and Indirect Findings at MR Imaging RadioGraphics, October 1, 2004; 24(suppl_1): S147 - S166. [Abstract] [Full Text] [PDF]

				V. De Leo, A. la Marca, and F. Petraglia Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome Endocr. Rev., October 1, 2003; 24(5): 633 - 667. [Abstract] [Full Text] [PDF]

				R. Azziz, E. Carmina, and M. E. Sawaya Idiopathic Hirsutism Endocr. Rev., August 1, 2000; 21(4): 347 - 362. [Abstract] [Full Text] [PDF]

				R. A. Lobo and E. Carmina The Importance of Diagnosing the Polycystic Ovary Syndrome Ann Intern Med, June 20, 2000; 132(12): 989 - 993. [Abstract] [Full Text] [PDF]

				A. Dunaif Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis Endocr. Rev., December 1, 1997; 18(6): 774 - 800. [Abstract] [Full Text]

				E. Diamanti-Kandarakis, G. Tolis, and A. J. Duleba Androgens and Therapeutic Aspects of Antiandrogens in Women Reproductive Sciences, July 1, 1995; 2(4): 577 - 592. [Abstract] [PDF]

				D. P. Lookingbill, L. M. Demers, R. E. Tigelaar, and A. R. Shalita Effect of Isotretinoin on Serum Levels of Precursor and Peripherally Derived Androgens in Patients With Acne Arch Dermatol, April 1, 1988; 124(4): 540 - 543. [Abstract] [PDF]

				R. S. RITTMASTER and D. L. LORIAUX Hirsutism Ann Intern Med, January 1, 1987; 106(1): 95 - 107. [Abstract] [PDF]

				R. L. De Villez and J. Dunn Female Androgenic Alopecia: The 3{alpha},17{beta}-Androstanediol Glucuronide/Sex Hormone Binding Globulin Ratio as a Possible Marker for Female Pattern Baldness Arch Dermatol, September 1, 1986; 122(9): 1011 - 1015. [Abstract] [PDF]